RANKL: A therapeutic target for bone destruction in rheumatoid arthritis

Sakae Tanaka, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Tsutomu Takeuchi

Research output: Contribution to journalReview articlepeer-review

57 Citations (Scopus)


Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive joint destruction. Recent studies have indicated the critical involvement of osteoclasts in bone destruction in RA. The osteoclast differentiation factor receptor activator of NF-κB ligand (RANKL), which belongs to the tumor necrosis factor superfamily, plays a critical role in osteoclast differentiation and bone destruction in RA. Denosumab, an antibody against human RANKL, efficiently suppressed the progression of bone erosion in RA patients in randomized controlled studies, and is considered as a putative therapeutic option for preventing bone destruction in RA.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalModern rheumatology
Issue number1
Publication statusPublished - 2018 Jan 2


  • Denosumab
  • osteoclast
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'RANKL: A therapeutic target for bone destruction in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this